[EYEG] Eyegate Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.68 Change: -0.01 (-0.59%)
Ext. hours: Change: 0 (0%)

chart EYEG

Refresh chart

Strongest Trends Summary For EYEG

EYEG is in the medium-term up 708% above S&P in 1 year. In the long-term down -63% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities3.86 M Cash From Investing Activities-20 K Cash From Operating Activities-1.77 M Gross Profit
Net Profit-2.81 M Operating Profit-1.1 M Total Assets2.55 M Total Current Assets2.49 M
Total Current Liabilities410 K Total Debt Total Liabilities410 K Total Revenue
Technical Data
High 52 week4.65 Low 52 week0.28 Last close3.11 Last change2.48%
RSI40.22 Average true range2.99 Beta1.02 Volume43.04 K
Simple moving average 20 days-5.05% Simple moving average 50 days-12.78% Simple moving average 200 days80.81%
Performance Data
Performance Week-2.82% Performance Month-13.75% Performance Quart-17.2% Performance Half579.43%
Performance Year484.75% Performance Year-to-date567.74% Volatility daily3.25% Volatility weekly7.28%
Volatility monthly14.92% Volatility yearly51.67% Relative Volume131.51% Average Volume34.27 K
New High New Low

News

2019-09-16 06:55:00 | EyeGate Pharma Reaches 75% Randomization of Patients in Pivotal Study

2019-09-03 06:55:00 | EyeGate Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference

2019-08-29 12:45:00 | EyeGate Pharma Announces Reverse Stock Split Effective August 30, 2019

2019-08-26 06:55:00 | EyeGate Pharma Reaches 50% Randomization of Patients in Pivotal Study

2019-08-08 06:55:00 | EyeGate Pharma Reports Second Quarter 2019 Financial Results and Provides Business Update

2019-08-05 12:21:16 | A Look At Benzinga Pro's Most-Searched Tickers For August 5, 2019

2019-08-05 09:00:40 | Eyegate Pharmaceuticals Receives FDA Approval To Begin PE Pilot Study

2019-08-05 06:55:00 | EyeGate Pharma Receives Approval from FDA to Initiate PE Pilot Study

2019-07-31 06:55:00 | EyeGate Pharma Announces Randomization of First 25% of Patients in Pivotal Study

2019-07-09 06:55:00 | EyeGate Files FDA Submission to Initiate PE Pilot Study

2019-06-26 06:55:00 | EyeGate Announces First Patient Enrolled in PRK Pivotal Study

2019-06-05 10:00:00 | EYEG: FDA Approves IDE. We Like Chances of Success of Upcoming OBG-PRK Pivotal Study

2019-06-03 06:55:00 | EyeGate Receives Approval from FDA to Initiate PRK Pivotal Study

2019-05-14 06:55:00 | EyeGate Pharma Receives Positive Nasdaq Listing Determination

2019-05-08 16:15:00 | EyeGate Pharma Reports First Quarter 2019 Financial Results and Provides Business Update

2019-05-02 14:00:00 | EYEG: EYEG Submits IDE to FDA Seeking Approval to Commence Pivotal PRK Study

2019-05-02 06:55:00 | EyeGate Files IDE with FDA for PRK Pivotal Study

2019-03-28 10:00:00 | EYEG: Our Take On EYEG Moving Towards OBG-PRK Pivotal Study

2019-03-26 06:55:00 | EyeGate Confirms Path to De Novo Filing with FDA

2019-03-01 16:05:00 | EyeGate Pharmaceuticals Reports Full Year 2018 Financial Results and Provides Business Update

2019-01-29 06:55:00 | EyeGate Pharmaceuticals to Present at BIO CEO & Investor Conference in New York City

2019-01-16 06:55:00 | EyeGate Pharmaceuticals Announces Meeting Date with FDA

2018-11-30 12:30:00 | EYEG: Is EyeGate Eyeing FDA Filings Following Positive OBG Data in Both PRK and PE?

2018-11-21 08:45:00 | Investor Expectations to Drive Momentum within Atomera, YogaWorks, Cellect Biotechnology, Eyegate Pharmaceuticals, Zealand Pharma A/S, and Polar Power — Discovering Underlying Factors of Influence

2018-11-14 11:20:00 | Drug Sales Up, Biotech Stocks Down, Here's a Profit Opportunity

2018-11-14 06:50:00 | Today’s Research Reports on Stocks to Watch: Viking Therapeutics and EyeGate Pharmaceuticals

2018-11-13 16:05:00 | EyeGate Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

2018-11-13 09:50:00 | 4 Healthcare Stocks Investors Are Watching In November

2018-11-13 06:55:00 | EyeGate Pharma Announces Positive Results in Punctate Epitheliopathy Study

2018-11-13 06:55:00 | EyeGate Pharma Announces Positive Results in Second PRK Study

2018-10-02 06:55:00 | EyeGate Pharmaceuticals Signs Technology Transfer and License Agreement with SentrX Animal Care

2018-09-28 11:45:00 | EYEG: Focus Is On OBG As U.S. Pilot Studies Fully Enrolled. Data Expected Q4. EGP-437 Ph3 AE Data Disappoints

2018-09-25 06:55:00 | EyeGate Pharmaceuticals Granted Additional 180 Days to Comply With Nasdaq Listing Rules

2018-09-24 06:55:00 | EyeGate Pharmaceuticals Completes Enrollment in Both PRK and PE Pilot Studies

2018-09-04 08:31:00 | EyeGate Announces Randomization of First Patients in Study for Punctate Epitheliopathies

2018-09-04 08:30:00 | EyeGate Announces Top-Line Results for Phase 3 Trial of EGP-437 in Anterior Uveitis

2018-08-29 08:30:00 | EyeGate Pharmaceuticals Announces Participation at the H.C. Wainwright 20th Annual Global Investment Conference

2018-08-20 08:30:00 | EyeGate Announces Enrollment of First Patient in PRK Pilot Study

2018-08-07 08:30:00 | EyeGate Pharmaceuticals Announces New Board Member, Peter Greenleaf

2018-08-03 08:30:00 | EyeGate Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update

2018-07-26 09:30:00 | EYEG: IDEs Approved. Both OBG Clinical Studies Set to Kick-Off

2018-07-25 08:06:01 | EyeGate Pharmaceuticals Stock Rose ~5.8% on July 24

2018-07-24 08:30:00 | EyeGate Announces FDA Approval of Two IDE Submissions for Ocular Bandage Gel

2018-07-10 07:45:00 | Free Pre-Market Technical Pulse on FibroGen and Three More Biotech Stocks

2018-06-22 08:30:00 | EyeGate Addresses Final FDA Action Item with Submission of IDE Amendment for Ocular Bandage Gel

2018-06-11 07:00:00 | Blog Exposure - FibroGen Completed Enrollment in US Phase-3 Clinical Program for Roxadustat in CKD Associated Anemia

2018-05-30 08:30:00 | EyeGate Files Supplement to Investigational Device Exemption to Commence Study in Punctate Epitheliopathy using the EyeGate Ocular Bandage Gel

2018-05-29 10:35:00 | EYEG: 3 of 4 FDA Questions Answered, OBG-PRK Study On-Track for Q3 Start

2018-05-25 21:37:45 | Want To Invest In EyeGate Pharmaceuticals Inc NASDAQ:EYEG? Here’s How It Performed Lately

2018-05-22 08:30:00 | EyeGate Addresses Majority of FDA’s Action Items with Submission of Investigational Device Exemption Amendment for Ocular Bandage Gel